Diabeloop, A Company Focused On Collective Intelligence

“We have great feedback from clinical outcomes, usability, people telling us that they have more time living rather than managing diabetes. But we’re no done, we want to make sure that this product is available to many more people. That means more countries, more connected devices, more indications.” – Erik Huneker, co-founder and CEO of Diabeloop.

Project Initiation

Dr. Guillaume Charpentier, diabetologist and president of the Center of Excellence for Research and Treatment of Diabetes (CERITD), initiated the medical research project.

Creation Of Diabeloop

Diabeloop was created by Dr. Guillaume Charpentier and Erik Huneker. Closely linked to the CEA-Leti.

Clinical Studies And First Round Of Funding

  • End of the fourth round of SP7 clinical trials, a pivotal study completed in partnership with 12 university hospitals, to ensure the safety and efficacy of the DBLG1 System
  • First round of funding of 13.5 million euros

The DBLG1 Obtained CE Marking

  • In November 2018, the first medical device developed by Diabeloop received CE marking, marketing authorization in Europe
  • Opening of the office in Paris

Record Breaking Second Round Of Funding In Therapeutic Artificial Intelligence

  • Conclusion of a Record-Breaking European Fundraising Effort of 31 million euros in the area of therapeutic artificial intelligence
  • Submission of the DBLG1 System to the French reimbursement agreement.
  • Clinical trials performed in children with Type 1 diabetes and adults with highly unstable diabetes (labile diabetes)

International Perspectives

  • Inauguration of our new headquarters in Grenoble (BHT2)
  • Opening of a Diabeloop GmbH subsidiary in Germany
  • R&D: exclusive development agreement with Terumo Corporation for the Japanese market
  • CE marking of DBL-hu, automated solution for the management of highly unstable Type 1 diabetes
  • Advanced discussions with German health insurers to make our DBLG1 algorithm available for the German market

Commercial Launch

  • DBLG1: commercial launch in various European countries (France, Germany, Netherlands, Switzerland, Spain, Italy…)
  • R&D: conclusion of development agreements with BIOCORP
  • Constitution of the US Advisory Board: Diabeloop Senior VP Zoe Heineman, Dr. Nicolas Argento, Dr. Jason C. Baker, Dr. David, M. Harlan, Dr. Camillo Ricordi and Dr. Paul Strumph
  • Extension of development agreement with Terumo Corporation to European markets

My Passion Rules My Life. Not Diabetes

  • Third round of financing of €70 million to accelerate international deployment
  • Extension of the development agreement with SOOIL
  • Launch of our new positioning “My passion rules my life. Not diabetes”
2011
2015
2017
2018
2019
2020
2021
2022
2011
2015
2017
2018
2019
2020
2021
2022

Project Initiation

Dr. Guillaume Charpentier, diabetologist and president of the Center of Excellence for Research and Treatment of Diabetes (CERITD), initiated the medical research project.

Our Ecosystem

The International Ambition Of A Diabetes Medtech

In November 2018, Diabeloop’s first medical device, the DBLG1, obtained CE marking, a marketing authorization for most of Europe. 

In 2019, the company submitted the DBLG1 System to French reimbursement agreement. 

In Germany, a market particularly interested by new technologies, Diabeloop is in the midst of conversations with health insurers. 

In the medium term, we are planning a progressive commercial launch in a majority of European countries.

Technological

CEA-Leti is an internationally-renowned tech research institute, and specializes in micro and nano-technologies. As a long-time partner of Diabeloop, it also shares a research laboratory with the company.

Medical

CERITD (research team of diabetologists), managed by Dr. Guillaume Charpentier, is a non-profit organization dedicated to diabetes research and treatment.

Medical Centers

Since 2010, Diabeloop has been conducting clinical trials, in which more than 300 patients have been involved, in collaboration with French and european university hospitals.

Our Partners And Supporters

  • Technological
  • Medical
  • Medical Centers

CEA-Leti is an internationally-renowned tech research institute, and specializes in micro and nano-technologies. As a long-time partner of Diabeloop, it also shares a research laboratory with the company.

Diabeloop's Management

  • Catherine Dunand, non-executive President of the Board
  • Erik Huneker, co-founder and CEO
  • Prof. Pierre-Yves Benhamou, CMO

Diabeloop's Supporters